People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Marker Therapeutics, Inc. | — | Biotechnology | Series B | $29.8M | $93.5M | 2024 |
Katharine Knobil at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Katharine Knobil on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Wilson | 1 | 11 |
| Joshua Silverman | 1 | 8 |
| Steven Elms | 1 | 5 |
| Peter Hoang | 1 | 2 |
| JOHN BONFIGLIO | 1 | 2 |
| GLYNN WILSON | 1 | 2 |
| Denis Corin | 1 | 2 |
| Juan Vera | 1 | 2 |
| Tracy Moore | 1 | 1 |
| Michael Loiacono | 1 | 1 |
| FREDERICK WASSERMAN | 1 | 1 |
| SHERRY GRISEWOOD | 1 | 1 |
| MARK REDDISH | 1 | 1 |
| David Eansor | 1 | 1 |
| DAVID LASKOW-POOLEY | 1 | 1 |
| MICHAEL J LOIACONO | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.